TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17292384

Group type: EXPERIMENTAL
Intervention: Reperfusion at 90 minutes (defined as ST resolution below 50% on VCG)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention or coronary artery bypass grafting
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Intervention before discharge
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: None of the reperfusion criteria of VCG
Number of subjects: 400
Study: 15786695

Group type: EXPERIMENTAL
Intervention: Cabergoline at 0.5 mg/week orally for 4 consecutive weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: No therapy (Control group)
Number of subjects: 20
Study: 17244442

Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraocular injections of steroids and anti-vascular endothelial growth factor agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sustained drug release devices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitrectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sheathotomy
Number of subjects: 0
Study: 10371654

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (21 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8604866

Group type: EXPERIMENTAL
Intervention: Forced-air rewarming
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cotton blankets (control group)
Number of subjects: 16
Study: 1894888

Group type: EXPERIMENTAL
Intervention: Diet with 30 en% fat, P/S = 1.0
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet with 40 en% fat, P/S = 0.3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-selected diets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Higher saturated fat diet
Number of subjects: 0
Study: 6216427

Group type: EXPERIMENTAL
Intervention: Locoid scalp lotion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Betnovate scalp application
Number of subjects: 30
Study: 31502856

Group type: EXPERIMENTAL
Intervention: Laser Acupuncture (LA), administered at traditional Chinese acu-points on the affected side, once a day, 5 times a week, for 4 weeks (N=43)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo Laser Acupuncture (placebo LA), administered using the same device and protocol, with the LA device switched off (N=41)
Number of subjects: 84
Study: 29885054

Group type: EXPERIMENTAL
Intervention: Balance Training (BT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (Ctrl)
Number of subjects: 43
Study: 26792354

Group type: EXPERIMENTAL
Intervention: Robotic thyroidectomy with central neck dissection (CND) using Da Vinci system
Number of subjects: 80

Group type: COMPARATOR
Intervention: Open conventional approach for thyroidectomy with CND
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Robotic thyroidectomy with CND
Number of subjects: 80
Study: 23084488

Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Closed reduction and maxillomandibular fixation
Number of subjects: 60
Study: 21959345

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 2128

Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 2128
Study: 19643944

Group type: EXPERIMENTAL
Intervention: Weekly, supervised, outpatient‐based exercise plus unsupervised home exercise
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard care of unsupervised home exercise
Number of subjects: 59
Study: 17241480

Group type: EXPERIMENTAL
Intervention: Moderate hypothermic CPB (ModHT group, 28 degrees C)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mild hypothermic CPB (MiHT group, 34 degrees C)
Number of subjects: 20
Study: 16237744

Group type: EXPERIMENTAL
Intervention: Multimodal optimization package
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional perioperative care
Number of subjects: 39
Study: 12182992

Group type: EXPERIMENTAL
Intervention: Octreotide s.c., 100 microg three times daily (n = 33)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Diphenoxylate and atropine orally, 2.5 mg four times daily (n = 28)
Number of subjects: 61
Study: 10443671

Group type: EXPERIMENTAL
Intervention: hPTH-(1-34)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: hPTH-(1-31)
Number of subjects: 10
Study: 7847975

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (6 doses of 2.4 g intravenously in the first 24 hours)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 100
Study: 2382916

Group type: EXPERIMENTAL
Intervention: 6% carboxyhemoglobin
Number of subjects: 41

Group type: COMPARATOR
Intervention: room air
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 4% carboxyhemoglobin
Number of subjects: 41
Study: 30987939

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (1000 mg once daily) plus prednisone (5 mg once daily) and ADT
Number of subjects: 1199

Group type: COMPARATOR
Intervention: Placebo plus ADT
Number of subjects: 1199

Group type: COMPARATOR
Intervention: Crossover from placebo to abiraterone acetate plus prednisone
Number of subjects: 1199
Study: 29807317

Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA) plus risperidone
Number of subjects: 70

Group type: COMPARATOR
Intervention: Risperidone plus placebo
Number of subjects: 70
Study: 26469879

Group type: EXPERIMENTAL
Intervention: CSPs (n=161)
Number of subjects: 161

Group type: COMPARATOR
Intervention: GPCs (n=355)
Number of subjects: 161
Study: 24440327

Group type: EXPERIMENTAL
Intervention: Digoxin therapy
Number of subjects: 350
Study: 22908694

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (FeSO₄) 100 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sodium iron ethylenediaminetetraacetic acid (NaFeEDTA) 100 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Iron polymaltose 100 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study: 20976161

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fish oil (3.2 g EPA and 2.0 g DHA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination treatment (Montelukast + Fish oil)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual diet (pre-treatment)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All treatments (Montelukast, Fish oil, Combination)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fish oil and Combination treatment
Number of subjects: 20
Study: 17449571

Group type: EXPERIMENTAL
Intervention: Whole-grain wheat bread
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Whole-grain rye crisp bread
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Whole-grain rye diet
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Whole-grain rye intake
Number of subjects: 15

Group type: COMPARATOR
Intervention: Refined wheat bread
Number of subjects: 15
Study: 16022854

Group type: COMPARATOR
Intervention: Depo-Provera
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Cyclofem
Number of subjects: 360
Study: 11963645

Group type: EXPERIMENTAL
Intervention: Test formulation (Dilavenil)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 20
Study: 9811158

Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg once daily for 8 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg once daily for 8 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mibefradil 150 mg once daily for 8 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mibefradil 200 mg once daily for 8 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mibefradil 40 mg intravenous dose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mibefradil 100, 150, or 250 mg oral multiple-dose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg and 100 mg once daily
Number of subjects: 12
Study: 7658777

Group type: EXPERIMENTAL
Intervention: Exercise test (positive result)
Number of subjects: 6296

Group type: EXPERIMENTAL
Intervention: Exercise test (negative result)
Number of subjects: 6296

Group type: COMPARATOR
Intervention: No exercise test
Number of subjects: 6296

Group type: EXPERIMENTAL
Intervention: Non-diagnostic test
Number of subjects: 6296

Group type: EXPERIMENTAL
Intervention: Symptomatic induced ischaemia
Number of subjects: 6296

Group type: EXPERIMENTAL
Intervention: Low work capacity
Number of subjects: 6296
Study: 2522756

Group type: EXPERIMENTAL
Intervention: Organoclay preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bentonite
Number of subjects: 0

Group type: COMPARATOR
Intervention: Kaolin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Silicone
Number of subjects: 0
Study: 79709

Group type: EXPERIMENTAL
Intervention: Nitrous oxide and oxygen for 24 hours
Number of subjects: 22

Group type: COMPARATOR
Intervention: No nitrous oxide
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nitrous oxide during the operation only
Number of subjects: 22
Study: 31869530

Group type: EXPERIMENTAL
Intervention: Provider communication intervention
Number of subjects: 98
Study: 30519872

Group type: EXPERIMENTAL
Intervention: Tai Chi training (five 60-min sessions per week for 12 weeks)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual physical activity (control group for 12 weeks)
Number of subjects: 170
Study: 29150457

Group type: EXPERIMENTAL
Intervention: EMLA + sucrose + ring block (RB)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: EMLA + sucrose + dorsal penile nerve block (DPNB)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: EMLA + sucrose
Number of subjects: 70

Group type: COMPARATOR
Intervention: EMLA alone
Number of subjects: 70
Study: 26225995

Group type: EXPERIMENTAL
Intervention: Black Bean (BB) meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Antioxidant Matched (AM) meal
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fiber Matched (FM) meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All meals
Number of subjects: 12
Study: 23477478

Group type: EXPERIMENTAL
Intervention: TAU + PCT
Number of subjects: 187

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 187
Study: 21052768

Group type: EXPERIMENTAL
Intervention: Maximal arm-ergometry
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maximal leg-ergometry
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sub-maximal leg-ergometry
Number of subjects: 0
Study: 18768048

Group type: EXPERIMENTAL
Intervention: Dexamethasone plus propofol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dexamethasone alone
Number of subjects: 80
Study: 15819763

Group type: EXPERIMENTAL
Intervention: Jaw thrust
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional Macintosh laryngoscopy
Number of subjects: 50
Study: 12441211

Group type: EXPERIMENTAL
Intervention: lercanidipine 10 mg/day
Number of subjects: 828

Group type: COMPARATOR
Intervention: amlodipine 5 mg/day
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: lacidipine 2 mg/day
Number of subjects: 828
Study: 10527003

Group type: EXPERIMENTAL
Intervention: Self-Rating Frenchay Activities Index (activity index)
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Self-Rating Barthel Index (disability index)
Number of subjects: 752
Study: 7723950

Group type: EXPERIMENTAL
Intervention: 150 mg rt-PA
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 100 mg rt-PA
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: rt-PA (150 mg or 100 mg)
Number of subjects: 23
Study: 11542203

Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 4

Group type: COMPARATOR
Intervention: Astemizole
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 6779303

Group type: EXPERIMENTAL
Intervention: Chlormethiazole (1 g at bedtime and 0.5 g early the following morning)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Placebo tablets
Number of subjects: 12

Group type: COMPARATOR
Intervention: Alcohol consumption (1.43 g alcohol/kg body weight)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control session (mineral water)
Number of subjects: 12
Study: 31818847

Group type: EXPERIMENTAL
Intervention: Benzodiazepine administration
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Opioid administration or titration
Number of subjects: 192
Study: 29531748

Group type: EXPERIMENTAL
Intervention: SUPPORT intervention
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 64
Study: 27469437

Group type: EXPERIMENTAL
Intervention: Artificial Teeth (AT) training (n=20)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Natural Teeth (NT) training (n=23)
Number of subjects: 43
Study: 25602710

Group type: EXPERIMENTAL
Intervention: Nepicastat 80mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nepicastat 160mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (0mg)
Number of subjects: 13
Study: 23684138

Group type: COMPARATOR
Intervention: No prophylaxis (Group 1, n = 133)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin (500 mg) 1 hour before procedure (Group 2, n = 141)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Single dose of fosfomycin tromethamine (FT) approximately 12 hours before procedure (Group 3, n = 137)
Number of subjects: 411
Study: 21903370

Group type: EXPERIMENTAL
Intervention: Symbicort® (SYM100)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Budesonide (BUD200)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Budesonide (BUD800)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Symbicort® (SYM200)
Number of subjects: 10
Study: 19164833

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (flour)
Number of subjects: 13
Study: 16914412

Group type: EXPERIMENTAL
Intervention: Retransfusion of pericardial suction blood during CPB (Group A)
Number of subjects: 35

Group type: COMPARATOR
Intervention: No retransfusion of pericardial suction blood during CPB (Group B)
Number of subjects: 35
Study: 15358704

Group type: EXPERIMENTAL
Intervention: Home cardiorespiratory polygraphy
Number of subjects: 75
Study: 10930321

Group type: EXPERIMENTAL
Intervention: Losartan potassium (50 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9049678

Group type: EXPERIMENTAL
Intervention: Dofetilide 4 micrograms/kg i.v. (n=33)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Dofetilide 8 micrograms/kg i.v. (n=32)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo (n=33)
Number of subjects: 98
Study: 8295040

Group type: EXPERIMENTAL
Intervention: Work-site health promotion programs for weight control and smoking cessation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Smoking cessation programs
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Weight control programs
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Baseline smokers
Number of subjects: 32
Study: 3554415

Group type: EXPERIMENTAL
Intervention: 1.5% mepivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1.5% prilocaine
Number of subjects: 40
Study: 29743071

Group type: EXPERIMENTAL
Intervention: First-line coil treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Second-line coil treatment
Number of subjects: 0
Study: 30226361

Group type: EXPERIMENTAL
Intervention: Nerve decompression
Number of subjects: 0

Group type: COMPARATOR
Intervention: No nerve decompression (Control)
Number of subjects: 0
Study: 24912465

Group type: EXPERIMENTAL
Intervention: Socially anxious individuals (SAD)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-socially-anxious participants
Number of subjects: 80
Study: 22387644

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg orally 2 hours prior to surgery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 19702474

Group type: EXPERIMENTAL
Intervention: Conceptual priming with obscure words that elicited meaningful associations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Familiarity-based recognition with late posterior potentials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Familiarity-based recognition with FN400 potentials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recognition tests with repeated stimuli
Number of subjects: 0
Study: 19213339

Group type: EXPERIMENTAL
Intervention: CT‐F (chemotherapy with FOLFOX protocol)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: CT‐F combined with HM
Number of subjects: 61

Group type: COMPARATOR
Intervention: HM (herbal medicines for reinforcing Shen and supplementing qi)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Blank control group (D)
Number of subjects: 61
Study: 15908833

Group type: EXPERIMENTAL
Intervention: Clinic-administered, abstinence-based incentive program; parent-directed contingency management; clinic-administered incentive program for parent participation; individual cognitive-behavioral therapy
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Parent-directed contingency management targeting substance use and conduct problems
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioral therapy for adolescents
Number of subjects: 19
Study: 12620167

Group type: EXPERIMENTAL
Intervention: Acetaminophen 4 g/d
Number of subjects: 0
Study: 10719262

Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) applied to frontal and parietal scalp sites of the unaffected hemisphere
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of digits using a dedicated electronic device
Number of subjects: 30
Study: 8791076

Group type: EXPERIMENTAL
Intervention: Proximal crescentic osteotomy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Proximal chevron osteotomy
Number of subjects: 75
Study: 1539816

Group type: EXPERIMENTAL
Intervention: Rectal piroxicam (40 mg 12 h before surgery, 20 mg with premedication, and 20 mg every 24 h for 72 h)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 3890506

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (40 mg orally)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Captopril (25 mg orally)
Number of subjects: 18
Study: 30464430

Group type: EXPERIMENTAL
Intervention: Empowering self-management model
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 26579854

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 22984818

Group type: EXPERIMENTAL
Intervention: Bladder filling with normal saline prior to trial of void (up to 500 mL or first sensation of fullness)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (catheter removed at 06:00 hours without filling)
Number of subjects: 52
Study: 21952714

Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation (19 weeks)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Nonaccelerated rehabilitation (32 weeks)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both accelerated and nonaccelerated rehabilitation
Number of subjects: 85
Study: 19082693

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day for 12 weeks
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day for 12 weeks
Number of subjects: 69
Study: 17686555

Group type: EXPERIMENTAL
Intervention: HCV peptide-vaccine IC41 (includes 5 MHC-class I and 3 MHC class-II-restricted epitopes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HCV peptide-vaccine IC41
Number of subjects: 0
Study: 15508562

Group type: EXPERIMENTAL
Intervention: Standardized patients and telemedicine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional distance learning
Number of subjects: 0
Study: 11975770

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study: 9023090

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (33 degrees C for 24 hours)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Normothermia (control group)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (for patients with coma scores of 5 to 7)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia
Number of subjects: 82
Study: 7942475

Group type: EXPERIMENTAL
Intervention: Intracoronary phentolamine, 2 mg, infused regionally through the balloon catheter before coronary artery angioplasty (n=12)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 32
Study: 2894161

Group type: EXPERIMENTAL
Intervention: rilmenidine (0.5 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: rilmenidine (1 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: rilmenidine (2 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: rilmenidine (3 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 29700944

Group type: EXPERIMENTAL
Intervention: Direct exercise supervision
Number of subjects: 50

Group type: COMPARATOR
Intervention: No direct exercise supervision
Number of subjects: 50
Study: 28777259

Group type: EXPERIMENTAL
Intervention: Acute stress condition (modified Trier Social Stress Test)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 26286147

Group type: EXPERIMENTAL
Intervention: Qing-Feng-Gan-Ke Granules (QFGKG) 12.0 g twice daily
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo 12.0 g twice daily
Number of subjects: 480
Study: 22729212

Group type: EXPERIMENTAL
Intervention: High-dose NRT (31.2 mg for the first 4 weeks, then 20.8 mg for 4 weeks)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Low-dose NRT (20.8 mg for 8 weeks)
Number of subjects: 184
Study: 21365172

Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 19

Group type: COMPARATOR
Intervention: Emollient
Number of subjects: 19

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 19
Study: 18294500

Group type: EXPERIMENTAL
Intervention: Low-dose rosuvastatin (5 mg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: High-dose rosuvastatin (40/80 mg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43
Study: 21606568

Group type: EXPERIMENTAL
Intervention: Galantamine (16 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 0